Abstract
Methods Ascites and sera samples from patients without known malignancy at the admission were collected. There were 14 stage-4 breast cancer (BC), 17 stage-4 ovarian cancer (OC) and 19 stage-4 endometrial cancer (EC) diagnosed later on. Control groups consisted of benign peritoneal fluids (n=53) and sera samples (n=25) from healthy subjects. Concentrations of sCD200 in the serum samples were quantified using ELISA kit. CEA (Beckman Coulter System. Catalog Number:33200), CA-19.9(Beckman Coulter System. Catalog Number:387687), CA-125 (Beckman Coulter System. Catalog Number:386357) and CA15.3 (Beckman Coulter System. Catalog Number: 387620). Levels were enumerated by fluoroenzyme immunoassay. Concentrations of sTRAIL in the serum samples were quantified using ELISA kits (Diaclone, France).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
